Abstract
Impaired inhibitory control accompanied by enhanced salience attributed to drug-related cues, both dorsolateral prefrontal cortex (dlPFC) functions, are hallmarks of drug addiction, contributing to worse symptomatology including craving. dlPFC modulation with transcranial direct current stimulation (tDCS) showed craving reduction in inpatients with cocaine use disorder (CUD). Our study aimed at assessing feasibility of a longer tDCS protocol in CUD (15 vs. the common five/10 sessions), and replicability of previous results.
In a randomized double-blind sham-controlled protocol, 17 inpatients were assigned to either a real-tDCS (right anodal/left cathodal) or a sham-tDCS condition, for 15 sessions. Primary outcome measures were self-reported craving, anxiety, depression, and quality of life. Secondary measures included sleepiness, readiness to change drug use, and affect. We also assessed cognitive function including impulsivity.
An 82% retention rate demonstrated feasibility. Partially supporting previous results, there was a trend for self-reported craving to decrease in the real-tDCS group more than the sham group, an effect that would reach significance with 15 subjects per group. Quality of life and impulsivity improved over time of treatment in both groups. Significant group × time interactions showed improvements after treatment only in the real-tDCS group for daytime sleepiness and readiness to change drug use. One-month follow-up suggested transient effects of tDCS on sleepiness and craving.
This study suggests that more subjects are needed to show a unique effect of real-tDCS on craving and to examine the duration of effect. Increased vigilance and motivation to change in the real-tDCS group suggest fortification of dlPFC-supported executive functions.
Competing Interest Statement
Parra and Datta hold shares in Soterix Medical Inc. They were involved in the design of this trial, but not in the execution of the trial, nor in the data analysis, or interpretation of the results.
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT03833583
Funding Statement
This study was supported by NIDA 271201800035C-0-0-1 tDCS to reduce craving in cocaine addiction (SBIR Phase I), by R01DA041528 to Dr. Goldstein, and by the Canadian Institutes of Health Research (Postdoctoral research award to Dr. Gaudreault).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All participants provided full written consent in accordance with both the Icahn School of Medicine at Mount Sinai and the Samaritan Daytop Village institutional review boards.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data acquired for this project are available upon request to Dr. Rita Z. Goldstein.
